Research programme: cyclo-oxygenase-2 selective inhibitors - Euclises Pharmaceuticals/Guangzhou Institutes of Biomedicine and Health

Drug Profile

Research programme: cyclo-oxygenase-2 selective inhibitors - Euclises Pharmaceuticals/Guangzhou Institutes of Biomedicine and Health

Alternative Names: Compound 1014; ECP 1014; GIBH-1014

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Developer Euclises Pharmaceuticals; Guangzhou Institutes of Biomedicine and Health
  • Class Benzopyrans; Carboxylic acids; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Pain

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 28 Mar 2017 Euclises Pharmaceuticals announces intention to submit IND to the US FDA for ECP 1014 in 2017
  • 09 Dec 2015 Euclises Pharmaceuticals receives notice of patent allowance for new class of compounds for treatment of cancer, pain and inflamation, in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top